Alkem Laboratories Limited has submitted to the Exchange, Outcome of the Board Meeting held on 28th May, 2026
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alkem Laboratories reported FY2026 consolidated revenue of Rs. 147,123 million, up 13.5% YoY from Rs. 129,645 million. Full-year profit after tax grew to Rs. 23,512 million versus Rs. 22,154 million, while basic EPS improved to Rs. 192.51 from Rs. 181.11. The Board approved audited annual results with an unqualified opinion from Deloitte Haskins & Sells. Exceptional items of Rs. 1,748 million included Rs. 747 million real estate impairment provision and Rs. 1,131 million towards new labour code compliance. The Board recommended a final dividend of Rs. 10 per share (total dividend including interim Rs. 43 = Rs. 53 per share), payable from 1st September 2026 to shareholders on record as of 7th August 2026. Mrs. Madhurima Singh was reappointed as Executive Director for 5 years.
Revenue growth of 13.5% YoY reflects strong operational performance. The dividend of Rs. 53 per share (including interim) provides ~4-5% yield at current prices. One-time exceptional charges impact Q4 but are non-cash/write-off items that do not affect operational business trajectory.